GenoScreen

GenoScreen corporate home

Press

About - Beyond genomic analysis

Since its foundation, GenoScreen has developed an ambitious R&D program. This is constantly used to improve the performance level and precision of its genomics and microbiological analysis tools. Our R&D staff has been part of many different international research programs in the healthcare, environmental and hygiene sectors.

Innovation portfolio

Our R&D programs have generated breakthrough technologies in the field of genomics and microbiology:

• Tests for bacterial pathogens,
• Analyses of complex microbiological ecosystems,
• Human genomics and personalized medicine.

Collaborative research

GenoScreen participates in several international research programs with a particular focus on Alzheimer’s disease, the epidemiological surveillance of pathogens and biodiversity.

Learn more

Publications

Discover the publications made with GenoScreen researchers.

Learn more

Business areas - Genomic and bioinformatic expertise

GenoScreen, a pioneering company in genomics and bioinformatics, has developed over the years, a portfolio of activities dedicated to the exploration and exploitation of the DNA molecule.

Multi-specialist provider serving academic and industrial R&D

GenoScreen offers a complete catalog of analytical services in genomics and bioinformatics: sequencing and transcriptome analysis of genomes of all types of organisms and microbial metagenomes.

Our strengths:

• The professionalism of a team of experienced genomics and bioinformatics experts,
• Use of sequencing platforms, high and medium throughput,
• The possession of a computer park that ensures the performance of analyzes and the security of data processed and archived,
• Advanced expertise in molecular microbiology,
• Characterization and analysis of microorganisms (all types of strains and microbiota).

Laboratory of high precision analyzes and tests in genomics and microbial metagenomics

GenoScreen carries out genomic tests, inspections and tests with its analysis laboratory operating. The expertise of its teams and the prevalence of collaborative mode bring confidence and security to a diversified clientele (all sizes, all sectors of activity).

Since 2016, our laboratory has been mobilized mainly for analyzes related to the identification and characterization of microorganisms and microbiota acting within organs, organisms or environment.

Discover our advanced genomic analysis solutions

A trusted partner to facilitate and accelerate R&D projects

GenoScreen mobilizes its technological resources and its R&D teams to meet the needs of academic and industrial researchers seeking expertise in genomics, metagenomics and bioinformatics.

Our interventions can be carried out as a partner or provider (services eligible for the Research Tax Credit in France). These activities are carried out under the guise of agreements that make it possible to specify the objectives pursued, the methods of carrying out the work and the desired guarantees regarding confidentiality.

Discover our R&D services

Supplier of solutions and tools dedicated to the detection and analysis of microorganisms

GenoScreen develops optimized solutions for detecting, identifying, characterizing and tracing microorganisms and for analyzing microbiotics of interest for diagnostic or therapeutic projects. The solutions developed concern healthcare, nutrition or environmental professionals.

Two product lines, consisting of a genomic compartment and a software suite, are undergoing continuous development:

• The Metabiote^® product line for the molecular microbiota study
• The Deeplex^® product line for molecular analysis of mycobacteria

GenoScreen also offers advanced training in relation to its expertise (genomics, metagenomics...).

History - A track record of growth and adaptation in the genomics market

Since its foundation in 2001, GenoScreen has been developing DNA analysis services that meet the needs of life science research groups.
The company’s growth is based on constant R&D investment and strong specialization in molecular microbiology.

This growth summarizes three phases:

• Service provision in genomics and bioinformatics, which enabled us to develop relationships with many life science research groups,
• The development of R&D activities, in collaboration with leading research groups,
• The introduction of an innovation strategy, and specialization in international niche markets in molecular microbiology.

This development pathway has enabled GenoScreen to commercialize three types of products/services:

• Scientific analyses and monitoring services in genomics and bioinformatics,
• Consultancy, expert analysis and training in our fields of expertise,
• Innovative kits for the detection and analysis of isolated microorganisms or microbial communities.

Corporate history

• 2001 Foundation of GenoScreen / RIO-certified platform
• 2004 GenoScreen launches its in-house R&D activities / INPI Trophy / Member of the NSL competitiveness cluster / CIR approval
• 2005 Our export sales account for over 20% of turnover
• 2006 Our first scientific publication / Filing of the first patent
• 2007 GenoScreen files a patent application on OTC biomarkers / MIRU M. tuberculosis typing kit launched
• 2009 Export sales account for over 30% of turnover export / IBISA-certified platform / Deloitte Technology Fast 50 award / Entry into the Oséo excellence community
• 2010 Launch of the GenoSat^® microsatellite library service / Initiation of the MEDIALZ project (Alzheimer’s disease)
• 2011 Start of the Patho-Ngen-Trace project (FP7) / ISI Innovation and Creativity Awards
• 2012 Implementation of the EQUIPEX technology platform (French government program) / Optimization of the metagenomics services
• 2013 Initiation of industrial R&D collaborations
• 2014 Launch of the MIRU-VNTR kit / Launch of Metabiote^®
• 2015 ISO 9001 Certification
• 2016 ISO 13485 Certification
• 2018 DIAMA project (evaluation and validation of the Deeplex® Myc-TB test in Africa and Europe)
• 2019 Launch of the Deeplex® Myc-TB kit / French soil mapping GenoSol / PEOPLE project
• 2020 Launch of the Brucella MLVA-16 range / CE-IVD mark for Deeplex^® Myc-TB
• 2021 Launch of the FIND/WHO Seq&Treat project
• 2022 Partnership with Illumina / Launch of services with Oxford Nanopore Technologies / Export sales reach 42%
• 2023 GenoBiome^® / Deeplex^® Myc-Lep / Deeplex^® HelP / Partnership with Cerba Healthcare

About - Mastering genomic information

Since 2001, GenoScreen is a pioneer of the use of sequencing, genotyping and bioinformatics. Its innovative genomics services and products address the needs of research groups in academia and industry.
GenoScreen also runs in-house innovation programs that fuel its technological lead and generate highly accurate, high-quality services and products.

Cutting-edge services in genomics, metagenomics and bioinformatics

GenoScreen offers a broad set of services in genomics, metagenomics and bioinformatics, based on high-powered technology platforms. 

The company has been serving a wide range of customers for over 15 years.

A stakeholder in microbiology research and innovation

GenoScreen is involved in many private- and public-sector research programs. It is developing a portfolio of analytical and monitoring tools in genomics, metagenomics and molecular microbiology.

Benefiting humankind and the environment

The services and innovations developed by GenoScreen address the needs of academic and industry-based researchers tackling a variety of issues in human health and environmental protection.

Accreditations and awards

• Label bpifrance Excellence 2023 awarded by bpifrance for the growth path.
• Label ePitches Euroquity 2017 awarded by bpifrance, enables the best start-ups to present their projects.
• Label Talents INPI Hauts-de-France 2016 Innovation category.
• Winner 2016, Initiative PME for the BIMM-SOL project, awarded by ADEME.
• Member of the Oséo Excellence Community, a group of 2,000 companies selected for their growth potential.
• Member of the bpifrance community "Les Accélérés".
• Member of the Adebiotech Think Tank.

What is the QPS list?

Read more ...